TNFAIP3 and central nervous system cancer: The increased survival of mice bearing intracranial tumors upon A20 targeting, and the decreased survival of glioma patients with elevated mRNA, both indicate that inhibition of A20 (or its downstream mediators) may be beneficial for glioma therapy.